Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV pre-exposure prophylaxis (PrEP) med lenacapavir. The twice-yearly PrEP ...

Now, Gilead Sciences has agreed to fork over $202 million to resolve allegations that it operated HIV speaker programs as a way to offer inducements for doctors to write prescriptions. In an ...

Nikos Pekiaridis / NurPhoto via Getty Images Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's profit got a lift from ...

If your heart aches for Black Honey’s cult glow but your wallet begs for mercy, why not give Maybelline’s $9 Lifter Glaze Oil Balm in Espresso Kiss (and maybe a couple other colors ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...

The brand’s first tinted lip balm utilizes hyaluronic microspheres that work like a hydration magnet, ensuring lips remain plump, moisturized, and juicy for hours.

This meant a mixed quarter for Gilead. On average, analysts were modeling $6.78 billion for revenue, but anticipating a lower per-share adjusted profit of $1.77. Annual profit guidance reduced ...

FOSTER CITY, Calif., May 07, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi ® (seladelpar), known as ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

NEW YORK, April 29 (Reuters) - Gilead Sciences (GILD.O), opens new tab agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying kickbacks to ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...